Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
OPS2011 Plenary Lecture Ernest M Wright, FRS
 

Summary: OPS2011 Plenary Lecture

Ernest M Wright, FRS
UCLA­David Geffen School of Medicine
Los Angeles, California
Sodium­glucose cotransporters (SGLTs) as new drug
targets for diabetes
Clinical interest in sodium­glucose cotransporters has intensified
with the recent development of new oral inhibitors of the renal
isoform, hSGLT2, for the treatment of type 2 diabetes. These drugs
have the potential for widespread use in the diabetes epidemic, but
how they work at the molecular level is poorly understood. In this
presentation I will first review recent advances on the physiology,
pharmacology, and molecular genetics of SGLTs, and then provide a
rationale for the use of SGLT inhibitors to control blood glucose
levels in diabetic patients. Next, I will review our recent work on the
interaction of SGLT inhibitors with SGLT1 and 2, and summarize the
published data on the Phase III clinical trials on one inhibitor,
dapagliflozin. Finally, I will outline the major unresolved questions
about the use of SGLT2 inhibitors and summarize our ongoing efforts

  

Source: Alvarez, Francisco J. - Department of Neuroscience, Cell Biology, and Physiology, Wright State University

 

Collections: Biology and Medicine